APA (7th ed.) Citation

Girolomoni, G., Feldman, S. R., Egeberg, A., Puig, L., Jung, J., Jung, H., & Lee, Y. (2024). Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Journal of Dermatological Treatment, 35(1), 1. https://doi.org/10.1080/09546634.2024.2434091

Chicago Style (17th ed.) Citation

Girolomoni, Giampiero, Steven R. Feldman, Alexander Egeberg, Luis Puig, Jinah Jung, Hojung Jung, and Younju Lee. "Long-term Real-world Evidence of SB5 (adalimumab Biosimilar) Treatment in Patients with Moderate-to-severe Psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)." Journal of Dermatological Treatment 35, no. 1 (2024): 1. https://doi.org/10.1080/09546634.2024.2434091.

MLA (9th ed.) Citation

Girolomoni, Giampiero, et al. "Long-term Real-world Evidence of SB5 (adalimumab Biosimilar) Treatment in Patients with Moderate-to-severe Psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)." Journal of Dermatological Treatment, vol. 35, no. 1, 2024, p. 1, https://doi.org/10.1080/09546634.2024.2434091.